Senate health committee to hold hearing on Trump drug pricing plan

Senate health committee to hold hearing on Trump drug pricing plan
© Greg Nash

President TrumpDonald John TrumpTrump rails against impeachment in speech to Texas farmers Trump administration planning to crack down on 'birth tourism': report George Conway on Trump adding Dershowitz, Starr to legal team: 'Hard to see how either could help' MORE's top health official will testify at a Senate hearing next month about the president’s proposal to reduce prescription drug costs.

Health and Human Services Secretary Alex Azar will testify at the June 12 Senate Health, Education, Labor and Pensions Committee hearing, the first time lawmakers will publicly examine Trump’s plan, which was unveiled earlier this month.

Committee Chairman Lamar AlexanderAndrew (Lamar) Lamar AlexanderConservative groups aim to sink bipartisan fix to 'surprise' medical bills GOP threatens to weaponize impeachment witnesses amid standoff Trump's trial a major test for McConnell, Schumer MORE (R-Tenn.) did not indicate whether the hearing will result in legislation.

ADVERTISEMENT

According to Trump, the administration can tackle many of the proposals on its own. But some more significant changes — like how Medicare pays for drugs — could require Congress.

Democrats have attacked Trump’s proposals for not going far enough. For example, his plan does not include a call for Medicare to negotiate drug prices directly.

Separately, House Ways and Means Committee Chairman Kevin BradyKevin Patrick BradyConservative groups aim to sink bipartisan fix to 'surprise' medical bills Trump economic aide says new tax proposal could be unveiled this summer Hoyer: Democratic chairmen trying to bridge divide on surprise medical bills MORE (R-Texas) said last week that he also intends to hold hearings on Trump’s drug pricing plan.

Most observers don’t expect Congress to take major action on a contentious issue like drug prices in an election year, but the hearings indicate there could at least be some discussion of the issue in Congress.